Table 2.

Associations between RAD50 protein expression in the tumor center and tumor periphery and clinicohistopathological data.

Variables	Subgroups	Tumor Center			Tumor Periphery
		Low (%)	High (%)	p Value	Low (%)	High (%)	p Value
Sex	Male	26.3	73.7	0.98	29.6	70.4	0.42
	Female	26.1	73.9		34.4	65.6
Age	≤72	28.8	71.2	0.39	30.6	69.4	0.82
	>72	24.1	75.9		31.9	68.1
Tumor stage	T1–2	23.5	76.5	0.65	32.1	67.9	0.68
	T3–4	26.2	73.8		29.6	70.4
Node stage	Negative	26.5	73.5	0.67	31.1	68.9	0.95
	Positive	24.1	75.9		30.8	69.2
Metastasis stage	M0	25.5	74.5	0.72	31.5	68.5	0.09
	M1	29.4	70.6		11.8	88.2
Histological Grade	1–2	26.1	73.9	0.88	31.3	68.7	0.98
	3	27.8	72.2		31.6	68.4
Vascular invasion	Absent	26.3	73.7	0.74	31.9	68.1	0.50
	Present	24.2	75.8		27.4	72.6
Perineural invasion	Absent	24.7	75.3	0.40	32.2	67.8	0.28
	Present	31.1	68.9		23.8	76.2
Adjuvant therapy	No	25.2	74.8	0.83	24.8	75.2	0.04
	Yes	26.6	73.4		38.8	61.2
Neoadjuvant therapy	No	23.8	76.2	0.14	27.1	72.9	0.16
	Yes	34.1	65.9		37.3	62.7
Tumor regression grade	0–1	50	50	0.14	50	50	0.22
	2–3	28.3	71.7		32.8	67.2
MSH6	Negative	50.0	50.00	0.43	0	100	0.35
	Positive	25.5	74.5		30.8	69.2
PMS2	Negative	55.6	44.4	0.04	44.4	55.6	0.36
	Positive	25.5	74.5		30.1	69.9

RAD50: DNA repair protein RAD50 homolog; MSH6: MutS protein homolog 6; PMS2: PMS1 homolog 2.